March 2011
Worldwide Biotech;Mar2011, Vol. 23 Issue 3, p5
Trade Publication
The article provides information on the takeover of drug company Kinaxo Biotechnologies GmbH by Evotech AG, Hamburg, Germany, to strengthen Evotech's leadership in pharmaceutical and biotechnology. It lists Kinaxo's capabilities which include cellular target profiling, kinaffinity and phosphoscout. It provides statements regarding the acquisition from Evotec chief executive officer (CEO) Werner Lanthaler, Kinaxo CEO Andreas Jenne, and Kinaxo co-founder Axel Ullrich. Financial details about the purchase of Kinaxo are provided.


Related Articles

  • Financings Roundup.  // BioWorld Today;2/10/2011, Vol. 22 Issue 28, p3 

    The article reports on the acquisition by Evotec AG of all shares in Kinaxo Biotechnologies GmbH for 12 million Euros.

  • Other News To Note.  // BioWorld Today;1/6/2011, Vol. 22 Issue 4, p2 

    This section offers news briefs concerning the biotechnology industry in the U.S. ArGen-X BV entered into alliance with Eli Lilly and Co. to generate human monoclonal antibody (mAb) candidates that act on diverse functional sites on Lilly targets. ImmunGene Inc. will collaborate with Cephalon...

  • More Megadeals Loom In the Drug Industry.  // Mergers & Acquisitions: The Dealermaker's Journal;Apr2000, Vol. 35 Issue 4, p10 

    Reports trends in consolidations between biotechnology companies and pharmaceutical industries in the United States. Deal between American Home Products (AHP) and Pfizer industries; List of other possible partners of AHP; Status of the Glaxo-SmithKline combination; Benefits of the...

  • Collaborations Between Biotech And Pharmaceutical Companies: Oct. 1 - Nov. 24, 2009.  // BioWorld Insight;11/30/2009, Vol. 17 Issue 48, p6 

    The article presents the biotechnology and pharmaceutical companies collaborations between October 1, 2009 to November 24, 2009. AC Immune SA collaborated with Bayer Schering Pharma AG for diagnostic imaging of Alzheimer's disease. PepTcell Ltd. subsidiary Biocopea Ltd. partners with Sosei Group...

  • European Patent Granted for Chemical Proteomics Applications.  // International Labmate;2011, Vol. 36 Issue 5, p23 

    The article reports that the European Patent Office has granted Kinaxo Biotechnologies a patent on chemical proteomics applications.

  • PRODUCTS & SERVICES.  // Hem/Onc Today;11/10/2009, Vol. 10 Issue 21, p40 

    This section describes several medical devices and services, such as KinAffinity from Kinaxo, imatinib of the Prix Galien USA which was awarded for best pharmaceutical product by the Novartis, and the fentanyl buccal soluble film, Onsolis, from Meda.

  • Past is Prologue. Hoffman, Michelle // Drug Discovery & Development;Aug2006, Vol. 9 Issue 8, p4 

    The author reflects on the science, art, and business of drug discovery and development in the U.S. She provides insights into the merger between biotechnology firm Genentech and Roche, a pharmaceutical company. The author also discusses the access of pharmaceutical firms to novel compounds and...

  • Do Biotechs Really Have the Upper Hand in Pharma Deals? Thiel, Karl // BioWorld Today;2/8/2011, Vol. 22 Issue 26, p1 

    The article examines whether amidst patent expirations and sparse pipelines at major pharmaceutical companies, biotechnological companies are in a strong position to negotiate advantageous deal terms in 2011. It predicts that most drug companies will try to buy their way out of declining...

  • Examining risk-modified trends in pharma & biotech deal-making. Coleman, Robin // Australasian Biotechnology;Oct2010, Vol. 20 Issue 3, p32 

    The article looks at the management of risks and opportunities in the fields of pharmaceutics and biotechnology, particularly in the deal-making market in Australia. Big pharmaceutical companies continue to manage risk and opportunity through research and development (R&D) efforts. Opportunities...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics